AreteMedical

lung function and inflammation.
anytime anywhere.
to help target the right intervention, earlier.
for asthma, COPD, long covid; chronic 🫁 disease.

[AreteMedical @AreteMedTech]

We are at #HLTH as part of an @innovateuk GBIP program - looking forward to meeting hospital groups, pharma digital innovators, and other looking to improve precision and prevention in asthma, COPD, and other long-term lung conditions

Booth 3651-24 - for demo - or link below

[brian lipworth @doclip1]

Just been learning about this genius three in one device

https://t.co/YnnMNKK5IJ

[Hello Tomorrow @hellotmrc]

🎉 Out of thousands of applications from across the globe, 7 extraordinary projects have been chosen as finalists for the Hello Tomorrow Challenge's Digital Health & Medical Devices track!

[Hello Tomorrow @hellotmrc]

Let’s see what the track finalists are working on:

🫁 @AreteMedTech (🇬🇧): Developing a low-cost, portable, web-connected, and rapid-use platform for testing lung inflammation, obstruction, and narrowing, enabling earlier intervention for chronic lung diseases like asthma.

[AreteMedical @AreteMedTech]

While guidelines have shifted towards this and the view is now pretty widely viewed as the way things should be done, there is still work to do on the way things are done.

What is preventing the shift?

https://t.co/5RcplrhdKk

[AreteMedical @AreteMedTech]

What we're reading:

7 years on from the Lancent Asthma Commission. A call to arms for precision medicine in asthma from the "treatable traits" paradigm.

[AreteMedical @AreteMedTech]

Wheels up at foggy LHR to Munich for @DxPx_Conference ✈️

While future version will be smaller, even our pre-market systems are acceptable carry-on in their drop / water resistance case 🧳

Looking forward to seeing some familiar faces and making new connections for 🫁

[AreteMedical @AreteMedTech]

🫁 We’ve made it to the finals of @hellotmrc Global Challenge!🫁

Our startup is one of the 7 finalists in ‘Digital Health & Medical Devices’, of 4500 total applications

See us pitch at the #HelloTomorrow2025 Summit in Paris on March 13-14, 2025!

👉https://t.co/hpuEMkJKkF

[AreteMedical @AreteMedTech]

Great to see long-awaited harmonization of guidelines between different groups, and the recognition of FeNO's critical role alongside spirometry.

Hopefully, this will come with funding to GP's to support adopting this!

[AreteMedical @AreteMedTech]

🫁 Exciting news! 🫁

Our solution to help prevent asthma attacks by best-in-class inflammation & airflow data been named one of @hellotmrc’s Deep Tech Pioneers! 🎉

Join us at the 10th Hello Tomorrow Global Summit in March 2025! #DeepTech #HTSummit2025 👉https://t.co/XHremJWh06

[AreteMedical @AreteMedTech]

Goal: move to 🥈

https://t.co/Cxxnl7ru0w

[AreteMedical @AreteMedTech]

Great to be at this iconic venue for the @R8ERHealth pitch event!

[AreteMedical @AreteMedTech]

free vectura ☮️ 🫁

[John Hurst @ProfHurst]

Thanks to @lizzieperl and @thetimes for the opportunity today to talk about lung health and #COPD in 🇬🇧.

Please, look after your 🫁.

[AreteMedical @AreteMedTech]

@vkhosla Who benefits at scale in the US from detecting chronic diseases earlier?

[Fridolin Steinbeis @FridoSteinbeis]

Proud to share our work on #longCovid phenotypes with focus on lung function abnormalities in patients with #fatigue #me as early view @ERSpublications A🧵 highlighting the main findings:
https://t.co/X0bgGUaLj5

[Will @toplungdoc]

https://t.co/VxvE4J4FBI Oscillometry is quicker to perform and provokes less symptoms than spirometry in patients with #IPF.

[ERS publications @ERSpublications]

ERJ Open Research: Asthma management has far-reaching effects on the economy, environment, healthcare and society, with greater impacts seen in patients with uncontrolled disease https://t.co/HfJ3CyYZ52

[Don Sin @donsin4]

~1/3 of patients have lung function abnormalities and residual lung abnormalities at 3 years post-#COVID19. #LongCovid is a real thing and will be with us for yrs to come.
https://t.co/SLXHMfo1Kr